bluuebunny/crossref_metadata_2025_split huggingface dataset:
Transient Chemo‐Mechanical Model of Lithium Plating Impacted by External Pressure
Authors: Meyer Julia M. , Mukherjee Partha P. , Collins Lincoln N. , Roberts Scott A. 
Published: December 2024

AbstractLithium anodes show great promise in commercial applications, but are hindered by lithium plating and dendrite growth which cause safety concerns during long‐term cell operation. Stack pressure is experimentally observed to improve cell lifetime; however, the relationship between stress and lithium deposition has remained difficult to elucidate. In this work, a transient, 3D, finite‐element model of the evolution of a lithium anode due to stripping and plating is developed. The evolution of a microscale protrusion on the anode surface is tracked over one charge‐discharge cycle with respect to stack pressure and lithium yield strength. Lithium plastic deformation, nonconformal anode‐separator contact, and separator porosity effects are accounted for. Over the course of several hours of stripping/plating, the anode surface evolves to a similar morphology under pressure regardless of the initial conditions due to lithium plastic deformation and hardening. The rate of this evolution highly depends on the applied pressure and assumed lithium yield strength.
Cl− Boosted Active and Stable Seawater Reduction on Pt/CoP Nanoarray Electrocatalysts
Authors: Liu Wei , Guo Xinlong , Jiang Zheheng , Yu Jiage , Zhou Linlin , Li Tianshui , Guo Yinghao , Li Shihang , Ding Boyu , Wang Kairui , Yang Yongqiang , Xin Huijun , Zhou Daojin , Kuang Yun , Sun Xiaoming 
Published: December 2024

AbstractHydrogen evolution in alkaline condition is kinetically unfavorable and requires active and stable electrocatalysts, not to mention the complex composition of seawater in catalytic alkaline seawater electrolysis. Herein, highly dispersed Pt on CoP nanoarray (denoted as Pt/CoP) is decorated as a hydrogen evolution electrocatalyst and further improved its activity by modulating the binding interaction between free Cl− in alkaline seawater and Pt/CoP. Compared to the blank control without Cl−, which requires an overpotential of 76 mV, this cathode exhibits an overpotential as low as 39 mV to reach −100 mA cm−2 after the addition of NaCl to the electrolyte. Characterizations and theoretical simulations demonstrate that Cl−coordinates with Pt species and strengthen the intermediates adsorption by reducing the electropositivity of the Pt sites. Furthermore, by coupling the Pt/CoP cathode with Ir/CoFe‐LDH anode, whose activity can also be boosted by Cl anions, the assembled seawater electrolyzer only required 1.75 V to 1 A cm−2 and stably operate for over 100 h. This work presents a major leap in electrode development for ultra‐high performance seawater electrolysis, highlighting that Cl−, which is generally considered detrimental, can be effectively harnessed.
Tuning the morphology of supramolecular aggregates for nanocarrier‐based drug delivery
Authors: Ji Xiongtao , Wang Na , Wang Jingkang , Huang Yunhai , Wang Ting , Huang Xin , Hao Hongxun 
Published: December 2024

AbstractDue to the unique drug delivery mode and specific therapy, nano‐formulations are of interest for biomedical applications and treating many diseases. However, traditional method of nano‐formulation construction via additional carriers or structural modifications of therapeutic drugs might be cumbersome or low loading‐efficient. Herein, the kinetics, accessible pathways, and final outcomes of supramolecular assembly processes of therapeutic drugs are investigated in detail. It was found that the supramolecular aggregates of cephradine (CEP) undergoes a morphological transformation from anisotropic nanofiber (EtOH) to isotropic spherical nanoparticle (H2O), similar to “plants took root, sprouted, blossomed and bore fruit.” Moreover, the assembly kinetics results reveal the assembly pathways of nucleation elongation in H2O and surface‐catalyzed secondary nucleation in EtOH. The method presented in this work has the potential to be used for efficiently designing specific nano‐formulations.
Nonrecurrent Triplication of 5q21.3q23.3: A Case Report and Review of the Literature
Authors: Ginter Jacob A. , Beaudry Sarah , Guseva Natalya , Nagy Jaime , Stence Aaron A. , Sidhu Alpa 
Published: December 2024

ABSTRACTTriplications involving 5q21.3q23.3 are rare, and a phenotype has not been established. Here, we present a 4‐month‐old male with dysmorphic facial features and congenital cardiac malformation. Chromosomal microarray identified a pathogenic triplication of 5q21.3q23.3 with chromosome analysis showing the extra 5q material inserted into 16q. Optical genome mapping (OGM) was performed to further characterize the triplication. We compared the clinical features of our proband with previous case reports of individuals with duplications or triplications in the region to identify a phenotype. Common features appear to include short stature, developmental delays, learning difficulties, and cardiac malformations. We discuss genes in the region with a reported role in cardiac development, hypothesize that the triplication may have resulted from microhomology‐mediated break‐induced replication, and discuss the utility and limitations of OGM in this case. To our knowledge, this is the first reported case of a de novo triplication of 5q21.3q23.3.
Identification of a Founder GLDN Variant Associated With “Lethal” Arthrogryposis in Nunavik Inuit: Implications for Obstetrical and Long‐Term Survivors' Management
Authors: McAdam Alexa , Ito Yoko A. , Richard Marilyn , Spiegelman Dan , Rochefort Daniel , Xiong Lan , Oskoui Maryam , Zielinski David , Rouleau Guy A. , Zhou Sirui ,   Care4Rare Canada Consortium, Boykott Kym M. , De Bie Isabelle 
Published: December 2024

ABSTRACTBiallelic variants in GLDN have recently been associated with lethal congenital contracture syndrome 11 (LCCS11), a form of fetal akinesia deformation sequence (FADS) with high neonatal mortality. In this report, we describe five individuals from two Canadian Inuit families originating from different communities in Nunavik all affected with FADS and harboring a rare homozygous missense variant, [NM_181789.4:c.82G >C p.(Ala28Pro)] in GLDN. Two pregnancies presented with significant obstetrical complications including placental abruption and hemorrhage. Four infants died shortly after birth, while one survived past the neonatal period. This individual, while apparently asymptomatic during infancy, then presented with progressive neuromuscular and respiratory compromise that became more evident in adolescence. Data from a Nunavik Inuit cohort demonstrated a minor allele frequency (MAF) of 0.03571 for this variant compared to 0.00001341 in the general population, suggesting a founder effect in the Nunavik Inuit population. Our findings support the presence of a founder variant associated with LCCS11 in Nunavik Inuit populations. Our data corroborate those of other reports, demonstrating that LCCS11 is not universally lethal, but long‐term survivors are at risk of progressive neuromuscular compromise. We also highlight in this report the significant obstetrical complications associated with this fetal‐onset condition.
Rhodium(III)‐Catalyzed Arylation of Dimethyl Itaconate: Facile Access to Substituted Benzylidenesuccinates
Authors: Takatsuji Yuito , Usuki Yoshinosuke , Satoh Tetsuya 
Published: December 2024

AbstractThe rhodium(III)‐catalyzed arylation of dimethyl itaconate with arylboronic acids proceeds smoothly under mild conditions to produce benzylidenesuccinates. The present reaction provides a simple synthesis route to benzylidenesuccinates, which are of interest due to their biological activities, from readily available substrates.
Glutathione Peroxidase‐Mimics Organoselenium Amines: Anti‐Ferroptotic Properties and an In Silico Study of 15‐Lipoxygenase‐2
Authors: Sodhi Nikhil , Kumar Manish , Yadav Manisha , Kadian Rajni , Atici Sena , Friedmann Angeli Jose Pedro , Singh Vijay P. 
Published: December 2024

AbstractIn search for better synthetic antioxidants, aminic organoselenides carrying amine and benzamide groups at ortho‐positions to the selenium atom were synthesized from alkyl halides and in situ generated sodiumselenolates as nucleophile by the sodium borohydride reduction of corresponding diselenides. The single crystal X‐ray structure of one compound showed the weak intramolecular Se⋅⋅⋅H interactions with free amine group. The presence of Se⋅⋅⋅H interactions was further confirmed using natural bond orbital (NBO) and atoms in molecules (AIM) calculations, respectively. The glutathione peroxidase enzyme (GPx)‐like antioxidant activity of all compounds was evaluated using thiophenol assay. The best antioxidant exhibited nearly 5 and 10 times greater activities than Oct2Se2 and Ph2Se2 used as references, respectively. The most active catalysts carrying a strong electron‐donating group were further investigated at different concentrations of thiol for determining the catalytic parameters. These GPx mimics have shown anti‐ferroptotic activity in a 4‐OH‐tamoxifen (TAM) inducible GPx4 knockout cell line and protected cells from cell death induced by loss of GPx4 enzyme. In silico molecular docking studies showed that all antioxidants demonstrated promising Moldock scores with human 15‐lipoxygenase‐2 enzyme.
Synthesis of Bridged and Fused Tetracycles via Rhodium‐Catalyzed C−H Allylation/Cycloaddition of Azomethine Imines with MBH Adducts and Allyl Acetates
Authors: Sun Yang , Wang Yiyan , Zhang Lijun , Zhong Rui , Wang Hui 
Published: December 2024

AbstractA rhodium‐catalyzed cascade C−H allylation combined with exo‐ and endo‐type [3+2] dipolar cycloaddition of aryl azomethine imines with Morita‐Baylis‐Hillman (MBH) adducts and allyl acetates is described. This process, which is operationally simple and proceeds efficiently in air and moisture under neat conditions, facilitates diverse bridged and fused tetracycles as single diastereomers. The reaction showcases a broad substrate scope and good functional group compatibility. Furthermore, its practicality is further demonstrated through successful scale‐up and synthetic applications.
Overview of Alzheimer's Disease Neuroimaging Initiative and future clinical trials
Authors: Weiner Michael W. , Kanoria Shaveta , Miller Melanie J. , Aisen Paul S. , Beckett Laurel A. , Conti Catherine , Diaz Adam , Flenniken Derek , Green Robert C. , Harvey Danielle J. , Jack Clifford R. , Jagust William , Lee Edward B. , Morris John C. , Nho Kwangsik , Nosheny Rachel , Okonkwo Ozioma C. , Perrin Richard J. , Petersen Ronald C. , Rivera‐Mindt Monica , Saykin Andrew J. , Shaw Leslie M. , Toga Arthur W. , Tosun Duygu , Veitch Dallas P. ,   for the Alzheimer's Disease Neuroimaging Initiative
Published: December 2024

AbstractThe overall goal of the Alzheimer's Disease Neuroimaging Initiative (ADNI) is to optimize and validate biomarkers for clinical trials while sharing all data and biofluid samples with the global scientific community. ADNI has been instrumental in standardizing and validating amyloid beta (Aβ) and tau positron emission tomography (PET) imaging. ADNI data were used for the US Food and Drug Administration (FDA) approval of the Fujirebio and Roche Elecsys cerebrospinal fluid diagnostic tests. Additionally, ADNI provided data for the trials of the FDA‐approved treatments aducanumab, lecanemab, and donanemab.More than 6000 scientific papers have been published using ADNI data, reflecting ADNI's promotion of open science and data sharing. Despite its enormous success, ADNI has some limitations, particularly in generalizing its data and findings to the entire US/Canadian population. This introduction provides a historical overview of ADNI and highlights its significant accomplishments and future vision to pioneer “the clinical trial of the future” focusing on demographic inclusivity.Highlights
The Alzheimer's Disease Neuroimaging Initiative (ADNI) introduced a novel model for public‐private partnerships and data sharing.
It successfully validated amyloid and Tau PET imaging, as well as CSF and plasma biomarkers, for diagnosing Alzheimer's disease.
ADNI generated and disseminated vital data for designing AD clinical trials.
The Alzheimer's Association clinical practice guideline for the diagnostic evaluation, testing, counseling, and disclosure of suspected Alzheimer's disease and related disorders (DETeCD‐ADRD): Validated clinical assessment instruments
Authors: Atri Alireza , Dickerson Bradford C. , Clevenger Carolyn , Karlawish Jason , Knopman David , Lin Pei‐Jung , Norman Mary , Onyike Chiadi , Sano Mary , Scanland Susan , Carrillo Maria 
Published: December 2024

AbstractUS clinical practice guidelines for the diagnostic evaluation of cognitive impairment due to Alzheimer's Disease (AD) or AD and related dementias (ADRD) are decades old and aimed at specialists. This evidence‐based guideline was developed to empower all—including primary care—clinicians to implement a structured approach for evaluating a patient with symptoms that may represent clinical AD/ADRD. As part of the modified Delphi approach and guideline development process (7374 publications were reviewed; 133 met inclusion criteria) an expert workgroup developed recommendations as steps in a patient‐centered evaluation process. The workgroup provided a summary of validated instruments to measure symptoms in daily life (including cognition, mood and behavior, and daily function) and to test for signs of cognitive impairment in the office. This article distills this information to provide a resource to support clinicians in the implementation of this approach in clinical practice. The companion articles provide context for primary care and specialty clinicians with regard to how to fit these instruments into the workflow and actions to take when integration of performance on these instruments with clinical profile and clinician judgment support potential cognitive impairment.
The Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD‐ADRD): Executive summary of recommendations for specialty care
Authors: Dickerson Bradford C. , Atri Alireza , Clevenger Carolyn , Karlawish Jason , Knopman David , Lin Pei‐Jung , Norman Mary , Onyike Chiadi , Sano Mary , Scanland Susan , Carrillo Maria 
Published: December 2024

AbstractUS clinical practice guidelines for the diagnostic evaluation of cognitive impairment due to Alzheimer's disease (AD) or a related dementia (ADRD) are two decades old. This evidence‐based guideline was developed to empower all clinicians to implement a structured approach for evaluating a patient with symptoms that may represent clinical AD/ADRD. An expert workgroup conducted a review of 7374 publications (133 met inclusion criteria) and developed recommendations as steps in an evaluation process. This summary briefly reviews core recommendations and details specialist recommendations of a high‐quality, evidence‐supported evaluation process aimed at characterizing, diagnosing, and disclosing the patient's cognitive functional status, cognitive–behavioral syndrome, and likely underlying brain disease so that optimal care plans to maximize patient/care partner dyad quality of life can be developed; a companion article summarizes primary care recommendations. If clinicians use the recommendations in this guideline and health‐care systems provide adequate resources, outcomes should improve in most patients in most practice settings.Highlights
US clinical practice guidelines for the diagnostic evaluation of cognitive impairment due to Alzheimer's disease (AD) or related dementias (ADRD) are decades old and aimed at specialists.
This evidence‐based guideline was developed to empower all—including primary care—clinicians to implement a structured approach for evaluating a patient with symptoms that may represent clinical AD/ADRD.
This summary focuses on recommendations appropriate for specialty practice settings, forming key elements of a high‐quality, evidence‐supported evaluation process aimed at characterizing, diagnosing, and disclosing the patient's cognitive functional status, cognitive–behavioral syndrome, and likely underlying brain disease so that optimal care plans to maximize patient/care partner dyad quality of life can be developed; a companion article summarizes primary care recommendations.
If clinicians use this guideline and health‐care systems provide adequate resources, outcomes should improve in most patients in most practice settings.
A whole‐brain functional connectivity model of Alzheimer's disease pathology
Authors: Prakash Ruchika S. , McKenna Michael R. , Gbadeyan Oyetunde , Shankar Anita R. , Pugh Erika A. , Teng James , Andridge Rebecca , Berry Anne , Scharre Douglas W. 
Published: December 2024

AbstractINTRODUCTIONAlzheimer's disease (AD) is characterized by the presence of two proteinopathies, amyloid and tau, which have a cascading effect on the functional and structural organization of the brain.METHODSIn this study, we used a supervised machine learning technique to build a model of functional connections that predicts cerebrospinal fluid (CSF) p‐tau/Aβ42 (the PATH‐fc model). Resting‐state functional magnetic resonance imaging (fMRI) data from 289 older adults in the Alzheimer's Disease Neuroimaging Initiative (ADNI) were utilized for this model.RESULTSWe successfully derived the PATH‐fc model to predict the ratio of p‐tau/Aβ42 as well as cognitive functioning in older adults across the spectrum of healthy and pathological aging. However, the in‐sample fit magnitude was low, indicating a need for further model development.DISCUSSIONOur pathology‐based model of functional connectivity included representation from multiple canonical networks of the brain with intra‐network connectivity associated with low pathology and inter‐network connectivity associated with higher levels of pathology.Highlights
Whole‐brain functional connectivity model (PATH‐fc) is linked to AD pathophysiology.
The PATH‐fc model predicts performance in multiple domains of cognitive functioning.
The PATH‐fc model is a distributed model including representation from all canonical networks.
Alzheimer's Association's funding portfolio: Insights from the International Alzheimer's and Related Dementias Research Portfolio (IADRP)
Authors: Kloske Courtney M. , Forner Stefania , Meyers Emily A. , Towers Albert E. , Snyder Heather M. , Carrillo Maria C. 
Published: December 2024

AbstractINTRODUCTIONAlzheimer's disease (AD) and related dementias (ADRD) present significant health challenges. Understanding their underlying biology, advancing existing and new therapies, and enhancing care for patients and caregivers are critical priorities.METHODSThis article utilizes data from the International Alzheimer's and Related Dementias Research Portfolio (IADRP) to analyze funding patterns from the Alzheimer's Association over the past decade.RESULTSAs the largest nonprofit funder of AD/ADRD research globally, the Alzheimer's Association has committed over $430 million, supporting a diverse range of studies across the entire spectrum of dementia‐related science. The funding landscape has evolved, reflecting new areas of investigation and collaboration with broader research initiatives.DISCUSSIONThis article highlights the dynamic nature of the Association's funding strategies and ongoing efforts to connect funding with additional supportive resources, thereby enhancing the overall research ecosystemHighlights
As the world's largest nonprofit funder of Alzheimer's disease and dementia science, the Alzheimer's Association's funding activities are strategically designed in partnership with the global research community to address scientific gaps in our knowledge to advance research.
A large part of the Association's funding portfolio depends on key partnerships and collaborations.
From 2019 to 2023, the Alzheimer's Association has allocated funding for more than 850 new research studies. The diversity of areas funded is clear across the Association's portfolio.
Beyond the Association's strong emphasis on supporting research through grant funding, there are also efforts to ensure the necessary ecosystem to support the career development of researchers and clinicians, maintaining ongoing support for current and future awardees, including convening and the Alzheimer's Association International Society to Advance Alzheimer's Research and Treatment (ISTAART).
Psychotropic medication usage in sporadic versus genetic behavioral‐variant frontotemporal dementia
Authors: Vargas‐Gonzalez Juan‐Camilo , Dimal Nico , Cortez Kasey , Heuer Hilary , Forsberg Leah K. , Appleby Brian S. , Barmada Sami , Bozoki Andrea , Clark David , Cobigo Yann , Darby R. Ryan , Dickerson Bradford C. , Domoto‐Reilly Kimiko , Galasko Douglas R. , Geschwind Daniel H. , Ghoshal Nupur , Graff‐Radford Neill R. , Grant Ian M. , Irwin David , Hsiung Ging‐Yuek Robin , Honig Lawrence S. , Kantarci Kejal , Léger Gabriel C. , Litvan Irene , Mackenzie Ian R. , Masdeu Joseph C. , Mendez Mario F. , Onyike Chiadi U. , Pascual Belen , Pressman Peter , Ramos Eliana Marisa , Roberson Erik D. , Rogalski Emily , Boeve Brad F. , Boxer Adam L. , Rosen Howie J. , Tartaglia Maria Carmela ,   ALLFTD Consortium Investigators
Published: December 2024

AbstractINTRODUCTIONPsychotropic medication (PM) use in behavioral‐variant frontotemporal dementia (bvFTD) is higher than in other dementias. However, no information exists on whether PM use differs between sporadic and genetic bvFTD.METHODSWe analyzed data from sporadic and genetic bvFTD participants with PM prescriptions in the Advancing Research and Treatment in Frontotemporal Lobar Degeneration/Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects study. We estimated ordinal odds ratio (OOR) of having more PM comparing sporadic and genetic bvFTD. Finally, we explored the neuropsychiatric symptom (NPS) combinations using classification and regression trees (CART).RESULTSWe included 263 with sporadic and 193 with genetic bvFTD. The OOR for sporadic bvFTD to be on PM was 1.75 (95% confidence interval: 1.21 to 2.53) for the fully adjusted model. CART revealed the most common NPS combination was apathy + personality changes in 18% of participants.DISCUSSIONParticipants with sporadic bvFTD were twice as likely to be on PM compared to genetic bvFTD. The reason for increased PM usage in sporadic bvFTD participants should be further investigated.Highlights
We report on patients with behavioral variant frontotemporal dementia (bvFTD).
We evaluated the psychotropic medication (PM) prescription at baseline in the cohort.
Patients with sporadic bvFTD had more prescriptions for PM than genetic patients.
The frequency of symptoms combination was different in sporadic and genetic bvFTD.
Microbe Engineering to Provide Drimane‐Type Building Blocks for Chiral Pool Synthesis of Meroterpenoids
Authors: Du Wenyu , Cheng Zhongyu , Pan Xingming , Liu Chenhao , Yue Mingyu , Li Tianhao , Xiao Zhixi , Li Lu‐Lu , Zeng Xuelan , Lin Xiaoxu , Li Fuzhuo , Dong Liao‐Bin 
Published: December 2024

AbstractDrimane‐type merosesquiterpenoids (DMT) are a class of natural products with diverse structures and broad biological activity. Classical DMT synthesis relies on atom‐inefficient plant‐derived chiral pool building blocks, while alternative drimane‐type building blocks such as drimenol and albicanol offer more direct routes but face production challenges. In this study, we engineered a microbial platform for efficient production of these building blocks. By optimizing the PhoN‐IPK system through rational engineering and incorporating a Nudix hydrolase, we achieved a drimenol production of 398 mg/L and high albicanol titers of 1805 mg/L in shake flasks and 3.5 g/L in a bioreactor. Structural analysis and molecular dynamics simulations of the engineered PhoN provided insights into its improved catalytic efficiency. We demonstrated the utility of this platform by synthesizing several DMT using albicanol as the starting material, reducing the number of synthetic steps and improving overall efficiency as compared to classical approaches.